Skip to main content
Vitaflo VIA Education Portal
  • PHENYLKETONURIA - INFANTS
  • PHENYLKETONURIA - CHILDREN
  • PHENYLKETONURIA - ADOLESCENTS AND ADULTS
  • PHENYLKETONURIA - MATERNAL
  • PHENYLKETONURIA - GMP
  • RARE DISORDERS OF PROTEIN METABOLISM
  • LIPID DISORDERS
  • GLYCOGEN STORAGE DISEASE
  • DRUG RESISTANT EPILEPSY - KETOGENIC DIET
  • DRUG RESISTANT EPILEPSY - K.VITA
  • KIDNEY DISEASE - PAEDIATRIC
  • KIDNEY DISEASE – ADULTS
  • NUTRITION SUPPORT
  • MULTILINGUAL RESOURCES
  • Product calculators and tools
  • CPD REFLECTION TOOL
  • K.VITA CALCULATOR
  • MCT CALCULATOR - LIPID DISORDERS
  • PKU TRIO CALCULATOR
  • KETOGENIC DIET NUTRITIONAL INTAKE TOOL
  • MPKU & LACTATION INTAKE ASSESSMENT
EVENTS
COURSES
BLOGS
Register Login
Source: https://www.vitaflo-via.com/disorder-resources/pku/pku-sphere-three-month-trial-case-study

Breadcrumb

  1. Home

PKU sphere™: A three month trial | Case Study

Want to access this resource?

REGISTER NOW LOGIN

Description

A case study showcasing the results of a three-month trial of PKU sphereTM, assessing potential clinical benefits in comparison to taking an amino acid based protein substitute.

The patient was an adult male diagnosed with PKU on newborn screening. The patient attended the metabolic clinic reporting symptoms including fatigue and mild anxiety.

Relevant History

Dietary: Patient followed the low protein diet strictly during childhood, but in adulthood found adhering to protein substitutes and the low protein diet increasingly difficult.

Note:

This was not a controlled study and so it is not possible to demonstrate a causal relationship between the patient’s change in diet and improvement in self-reported symptoms.

In addition, this informal process of trialling a new product and recording several outcomes before and after was developed in conjunction with the patient. This was to support the case for access to his preferred protein substitute from his healthcare provider. This type of external motivation can sometimes affect results.

PKU sphere™ is a Food for Special Medical Purposes. All information is correct at the time of publishing (August 2020).

GMP-based protein substitutes were newly available and have been suggested to improve dietary adherence in adult PKU patients.(1,2) 

Overall Aim

A three-month trial of PKU sphere was conducted to assess what (if any) clinical benefits were experienced by the patient, compared to when taking his usual amino acid-based protein substitute at baseline.

Dietetic Intervention

Assessments: All parameters were completed at baseline (whilst taking usual protein substitute) and after 3 months of PKU sphere intake including:

  • Biochemical parameters: plasma phenylalanine: indicating metabolic control and vitamin B₁₂ and folate: indicating nutritional status.
  • Dietary adherence and nutritional intake: dietary assessments completed by specialist metabolic dietitian.
  • Psychosocial outcomes: Fatigue Severity Scale (3), SF-36 (4), assessing quality of life, cognitive failures questionnaire (5) assessing cognitive functioning, Hospital Anxiety and Depression Scale (6).
  • Palatability and tolerance: self-reported by patient during dietary assessments.
Parameter Reference
Range
Baseline Following 3
month trial
Clinical Interpretation
Plasma
phenylalanine (µmol/L)
120 - 600 1297 560 Clinically significant improvement
Plasma Vitamin B₁₂ (pg/mL)

 

197 - 771 264 416 Clinically significant improvement
Plasma Folate (ng/mL) 2.9 - 26.8 5.1 10.6 Clinically significant improvement
Protein intake (g/day) n/a <0.5g/kg/day >1g/kg/day Clinically significant improvement
Fatigue Severity Scale n/a 22 12 Clinically significant improvement
Quality of life (SF-36) n/a 88 (45th %ile) 98 (75th %ile) Stable
Cognitive failures questionnaire n/a 26/100 3/100 Clinically significant improvement
Hospital Anxiety and Depression Scale n/a A - 9 (86th %ile, mild anxiety)
D - 6 (64th %ile, normal range)
A - 2 (18th %ile, normal range)
D - 1 (28th %ile, normal range)
Clinically significant improvement in anxiety symptoms

 

The patient reported that PKU sphere was more palatable and tolerable compared to his previous amino acid-based protein substitute. This is undoubtedly important for patients who are expected to follow a restrictive and difficult lifelong diet to effectively manage their condition.

Overall, use of this product has allowed the patient to achieve considerably better metabolic control and achieve the target for phenylalanine recommended in European guidelines for PKU (7). His nutritional status has also improved, as evidenced by improvements in biochemical markers and dietary assessment of total protein intake.

The patient completed several validated, self-reported questionnaires to assess psychosocial outcomes (on advice from a neuropsychologist). All assessments revealed improvements in fatigue, quality of life, cognitive functioning and anxiety after taking PKU sphere for 3 months.

Following the 3 month trial, the patient continued to take PKU sphere. Bloodspot results remained much improved (655µmol/L and 475µmol/L) compared to their baseline plasma level (1297µmol/L) whilst taking the previous protein substitute. This demonstrated that the patient was able to achieve longer-term adherence, whilst taking PKU sphere as part of a therapeutic diet.

The data presented supports that PKU sphere improved clinical outcomes and dietary adherence for this patient, compared to when taking their previous amino acid-based protein substitute.

  1. van Calcar SC, MacLeod EL, Gleason ST, Etzel MR, Clayton MK, Wolff JA, et al. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. The American Journal of Clinical Nutrition. 2009;89(4):1068-77.
  2. Ney DM, Stroup BM, Clayton MK, Murali SG, Rice GM, Rohr F, et al. Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial. The American Journal of Clinical Nutrition. 2016.
  3. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-3.
  4. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical care. 1992:473-83.
  5. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The cognitive failures questionnaire (CFQ) and its correlates. British journal of clinical psychology. 1982;21(1):1-16.
  6. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatrica scandinavica. 1983;67(6):361-70.
  7. van Spronsen FJ, van Wegberg AM, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. The Lancet Diabetes & Endocrinology. 2017.
DOWNLOAD

Authors

  • Charlotte Ellerton

    Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, UK

  • Dr Lynne Aitkenhead

    Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, UK

Published

  • 01/08/2020

TAGS

PKU & GMP

OTHER RESOURCES YOU MAY BE INTERESTED IN

healthcare professional looking at a slide in a microsope
Fallstudie

Erkenntnisse aus der größten umfassenden Langzeitstudie mit PKU sphere® bei Kindern und Jugendlichen 1-4

27/01/2026
stack of books
Evidence Summary

The effects of cGMP on general health status in children with PKU

09/12/2025
Man opening a book with light spilling out of it
Event Recording

Highlights from the Element clinical trial and practical take aways for GMP use in PKU

21/11/2025

WE HAVE A WEALTH OF RESOURCES FOR

pku-infant.svg
pku-infant-white.svg

PKU - Infants

pku-children.svg
pku-children-white.svg

PKU - Children

pku-adolescents-adults.svg
pku-adolescents-adults-white.svg

PKU - Adolescents and Adults

mpku.svg
mpku-white.svg

Maternal PKU

pku-gmp.svg
pku-gmp-white.svg

PKU & GMP

Rare disorders
rare-disorders-white.svg

Rare Disorders of Protein Metabolism

Lipid disorder
Lipid disorder white

Lipid Disorders

gsd.svg
GDS white

Glycogen Storage Disease

Ketogenic diet
Ketogenic diet white

Drug Resistant Epilepsy - Ketogenic Diet

k-vita-icon.svg
k-vita-icon-white.svg

Drug Resistant Epilepsy - K.Vita

kidney-disease-child.svg
kidney-disease-child-white.svg

Kidney Disease - Paediatric

kidney-disease-adult.svg
kidney-disease-adult-white.svg

Kidney Disease – Adults

Nutrican support
Nutrican support white

Nutrition Support

PKU sphere™: A three month trial | Case Study
  • DISORDER AREAS
  • Phenylketonuria - Infants
  • Phenylketonuria - Children
  • Phenylketonuria - Adolescents and Adults
  • Phenylketonuria - Maternal
  • Phenylketonuria - GMP
  • Rare Disorders of Protein Metabolism
  • Lipid Disorders
  • Glycogen Storage Disease
  • Drug Resistant Epilepsy - Ketogenic Diet
  • Drug Resistant Epilepsy - K.Vita
  • Kidney Disease - Paediatric
  • Kidney Disease - Adults
  • Nutrition Support
  • Multilingual Resources
  • TOOLS
  • CPD Reflection Tool
  • K.Vita Calculator
  • MCT Calculator
  • PKU Trio Calculator
  • mPKU & Lactation Intake Assessment
  • BLOG
  • Blogs
  • CONTACT
  • Contact Us
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Accessibility Statement
  • Follow us on LinkedIn
Vitaflo - Enhancing Lives Together

Vitaflo International Ltd, Suite1.11, South Harrington Building, 182 Sefton Street, Brunswick Business Park, Liverpool L3 4BQ, UK

©2026 Vitaflo International Limited

® Reg. Trademarks of Societe des Produits Nestle S.A © 2025 All rights reserved Societe des Produits Nestle S.A, Vevey, Switzerland